8-K: Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome announces its full year 2024 financial results, highlighting progress in its clinical pipeline and a cash runway extending into 2027.

Summary

• Immunome reported its financial results for the year ended December 31, 2024.
• The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, not including $172.5 million from a January 2025 financing.
• Immunome's current cash runway is expected to extend into 2027.
• Research and development expenses for the year were $129.5 million, including $5.1 million in stock-based compensation.
• In-process research and development expenses were $152.3 million, related to business development activity.
• General and administrative expenses totaled $33.0 million, including $10.6 million in stock-based compensation.
• The company reported a net loss of $293.0 million for the year ended December 31, 2024.
• Topline data for the Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors is expected in the second half of 2025.
• The first patient was dosed in the Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.
• An IND was submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, progress in clinical trials, and upcoming milestones. However, the significant net loss tempers the overall outlook.

Positives

• The company has a strong cash position of $217.3 million as of December 31, 2024, which is expected to extend the cash runway into 2027.
• A successful public offering in January 2025 raised $172.5 million.
• The Phase 3 RINGSIDE study of varegacestat is expected to report topline data in the second half of 2025.
• The Phase 1 clinical trial of IM-1021 has dosed its first patient.
• An IND has been submitted for IM-3050, with a Phase 1 trial expected later in 2025.

Negatives

• The company reported a significant net loss of $293.0 million for the year ended December 31, 2024.
• In-process research and development expenses were high at $152.3 million.

Risks

• The company's future performance is dependent on the success of its clinical trials and regulatory approvals.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's Annual Report on Form 10-K for the year ended December 30, 2024, being filed with the SEC today, and in Immunome's other filings with the SEC, outlines other risks and uncertainties.

Future Outlook

Immunome expects topline data for the Phase 3 RINGSIDE Part B trial in the second half of 2025, anticipates initiating a Phase 1 clinical trial for IM-3050 later in 2025, and believes its current cash runway will extend into 2027, supporting multiple clinical milestones.

Management Comments

• Immunome's efficient execution in 2024 laid the foundation for a productive 2025, according to Clay B. Siegall, Ph.D., President and Chief Executive Officer.
• The company is pleased with the progress of its pipeline and expects that its recent financing will support multiple clinical milestones.
• The company believes the RINGSIDE trial of varegacestat will demonstrate significant benefits for patients with desmoid tumors.
• The company's team is achieving its vision of a broad, differentiated portfolio of ADCs.

Industry Context

Immunome is operating in the competitive oncology space, focusing on targeted therapies like ADCs and radioligand therapies. The company's progress in clinical trials and IND submissions positions it to potentially address unmet needs in cancer treatment.

Comparison to Industry Standards

• Many biotechnology companies developing novel cancer therapies, such as ADC's, are in competition with Immunome.
• Companies such as Seagen and ImmunoGen are leaders in the ADC space, and Immunome is working to develop differentiated ADC candidates.
• The $172.5 million raised in the public offering is a significant amount of capital that will allow Immunome to advance its pipeline.
• The cash runway extending into 2027 provides Immunome with financial stability to execute its clinical development plans.

Stakeholder Impact

• Shareholders will be interested in the financial results and pipeline progress.
• Employees are likely to be motivated by the company's advancements and financial stability.
• Patients with desmoid tumors may benefit from the potential approval of varegacestat.
• The company's suppliers and partners may benefit from its continued growth and development.

Next Steps

• Report topline data for the Phase 3 RINGSIDE Part B trial in the second half of 2025.
• Continue the Phase 1 clinical trial of IM-1021.
• Initiate a Phase 1 clinical trial for IM-3050 later in 2025.
• Advance preclinical ADC candidates IM-1617, IM-1340, and IM-1335 through IND-enabling work.

Key Dates

Keywords

Immunome, varegacestat, IM-1021, IM-3050, ADC, clinical trials, financial results, cancer therapy, oncology, biotechnology